“As US biotech companies, how do we continue to differentiate and create novel breakthrough assets? I think it’s leveraging AI,” said Sean McClain, founder and CEO of Absci. McClain and Christian Stegmann, senior vice president of drug creation, sit down with Bloomberg Intelligence analyst Andrew Galler in this episode of the Vanguards of Health Care podcast to discuss Absci’s generative AI platform and developing best-in-class biologics.

Butterfly Leads the Drive on Semiconductor to Make the Most Out of Ultrasound
43:42

Citizen Health’s Plan to Put an AI Advocate in Every Patient’s Pocket
50:47

Distalmotion’s Approach to Spread Surgical Robots to More
36:38